Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

639 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Herrera AF, Goy A, Mehta A, Ramchandren R, Pagel JM, Svoboda J, Guan S, Hill JS, Kwei K, Liu EA, Phillips T. Herrera AF, et al. Among authors: svoboda j. Am J Hematol. 2020 Jan;95(1):18-27. doi: 10.1002/ajh.25659. Epub 2019 Nov 6. Am J Hematol. 2020. PMID: 31621094 Free PMC article. Clinical Trial.
Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA. Andreadis C, et al. Among authors: svoboda j. Bone Marrow Transplant. 2005 Dec;36(11):955-61. doi: 10.1038/sj.bmt.1705178. Bone Marrow Transplant. 2005. PMID: 16205727
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy A. Mato AR, et al. Among authors: svoboda j. Cancer. 2012 Jul 15;118(14):3565-70. doi: 10.1002/cncr.26731. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180256 Free article.
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, Valentinetti M, Mrkulic M, Azzollini K, Gadaleta G, Bhattacharyya PK, Zenreich J, Pascual LN, Yannotti K, Kdiry S, Howlett C, Strelec L, Porter D, Bejot C, Goy A. Mato AR, et al. Among authors: svoboda j. Am J Hematol. 2015 Jun;90(6):487-92. doi: 10.1002/ajh.23983. Epub 2015 Mar 30. Am J Hematol. 2015. PMID: 25691474 Free article. Clinical Trial.
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A. Howlett C, et al. Among authors: svoboda j. Br J Haematol. 2015 Aug;170(4):504-14. doi: 10.1111/bjh.13463. Epub 2015 Apr 24. Br J Haematol. 2015. PMID: 25907897 Free article. Review.
639 results